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Summary
Interleukin-18 (IL-18) is an immunostimulatory cytokine that augments antibody-dependent 
cellular cytotoxicity mediated by human NK cells against antibody-coated lymphoma cells in vitro 
and that has antitumor activity in animal models. Ofatumumab is a CD20 monoclonal antibody 
with activity against human B cell lymphomas. A phase I study of recombinant human (rh) IL-18 
given with ofatumumab was undertaken in patients with CD20+ lymphoma who had undergone 
high-dose chemotherapy and autologous peripheral blood stem cell transplantation. Cohorts of 3 
patients were given intravenous infusions of ofatumumab 1000 mg weekly for 4 weeks with 
escalating doses of rhIL-18 as a intravenous infusion weekly for 8 consecutive weeks. Nine male 
patients with CD20+ lymphomas were given ofatumumab in combination with rhIL-18 at doses of 
3, 10, and 30 μg/kg. No unexpected or dose-limiting toxicities were observed. The mean reduction 
from pre-dose levels in the number of peripheral blood NK cells after the first rhIL-18 infusion 
was 91%, 96%, and 97% for the 3, 10, and 30 μg/kg cohorts, respectively. Serum concentrations of 
interferon (IFN)-γ and chemokines transiently increased following IL-18 dosing. rhIL-18 can be 
given in biologically active doses by weekly infusions in combination with ofatumumab after 
PBSCT to patients with lymphoma. A maximum tolerated dose of rhIL-18 plus ofatumumab was 
not determined. Further studies of rhIL-18 and CD20 monoclonal antibodies in B cell 
malignancies are warranted.
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Introduction
Non-Hodgkin lymphomas (NHL) are the most common of the hematologic malignancies 
(1). Despite substantial improvement in treatment of B cell lymphomas since the advent of 
rituximab, approximately 30% of patients with diffuse large B cell lymphoma (DLBCL) and 
virtually all patients with advanced stage indolent lymphoma will relapse after treatment 
with rituximab-based regimens. High-dose therapy and autologous peripheral blood stem 
cell transplantation (PBSCT) is the treatment of choice for eligible patients with relapsed 
DLBCL that is responsive to salvage chemotherapy (2–5). PBSCT is also a reasonable 
treatment option for patient with relapsed indolent lymphoma. The overwhelming cause of 
treatment failure after PBSCT is progression of lymphoma. Substantial improvement in the 
outcome of PBSCT for NHL will require strategies that can reduce the risk of relapse after 
transplantation. One approach is post-transplant immunotherapy to try to eliminate 
chemotherapy-resistant tumor cells (6). The state of minimal residual disease that can occur 
post-transplant may be a particularly promising setting for cancer immunotherapy, as the 
latter is most effective against a relatively small tumor burden.
Our previous studies indicate that a major obstacle to successful cancer immunotherapy after 
PBSCT is acquired STAT4 deficiency. We have found that IFN-γ production during IL-12 
therapy is markedly defective in cancer patients who have undergone high-dose 
chemotherapy and PBSCT (7, 8). Defective IFN-γ production in this setting is due to a 
profound and selective deficiency in STAT4 (7, 8). STAT4 deficiency in the immune system 
of cancer patients is expected to impair clinical immunotherapy that requires Th1 immune 
responses and optimal production of IFN-γ. Preclinical studies indicate that IFN-γ plays a 
pivotal role in the cellular immune response to tumors (9–11). Therefore, development of 
strategies to circumvent STAT4 deficiency is critical for effective cancer immunotherapy 
after PBSCT. STAT4 is not known to participate in the signaling pathways required for IFN-
γ production in response to IL-18 or after stimulation of NK cells via ligation of CD16 (12, 
13). It is therefore rational to combine rhIL-18 with CD20 monoclonal antibodies for the 
immunotherapy of lymphoma after PBSCT.
IL-18 is an immunostimulatory cytokine that regulates both innate and adaptive immune 
responses (14, 15). Administration of IL-18 to cancer patients is safe and causes the in vivo 
activation of human NK cells (16, 17). A phase I trial of rhIL-18 plus rituximab has 
confirmed the safety and immunologic activity of this combination in patients with relapsed 
and refractory lymphomas (18). Administration of rhIL-18 could promote antitumor immune 
responses by augmenting ADCC of NK cells and monocytes, stimulating production of IFN-
γ, MIG, and IP-10, enhancing differentiation of Th1 cells, and facilitating recruitment of 
effector cells to tumor sites. Other cytokines, including IL-2, IL-12, and GM-CSF, have been 
given in combination with rituximab to treat patients with lymphoma (19–23). However, 
IL-18 may be preferable to these cytokines for combined immunotherapy with CD20 
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monoclonal antibodies. IL-2 and IL-12 can augment antibody-dependent cellular 
cytotoxicity (ADCC) mediated by NK cells, but do not appear to significantly enhance 
ADCC by monocytes or macrophages (24–27). In contrast, GM-CSF preferentially 
stimulates ADCC by monocyte/macrophages and has little effect on NK cell cytolytic 
activity (25, 27, 28). IL-18 can strongly activate both NK cells and monocyte/macrophages 
(14, 15, 29), and hence might be more potent than IL-2, IL-12, or GM-CSF in enhancing 
ADCC against antibody-sensitized lymphoma cells. Furthermore, administration of IL-2 
leads to the in vivo expansion of CD25+ CD4+ regulatory T cells, which can inhibit IFN-γ 
production and antitumor immune responses (30–32). Both standard dose and high dose 
chemotherapy cause an acquired STAT4 deficiency in lymphoma patients, which leads to 
impaired IL-12-induced immune responses (33–35). Therefore, IL-18 may prove more 
effective than IL-2 or IL-12 for cytokine-based immunotherapy of lymphoma.
Ofatumumab is a fully human IgG1 monoclonal antibody that binds to different epitope of 
CD20 than that recognized by rituximab (36). Ofatumumab can be safely given to patients 
with relapsed and refractory lymphoma (37). Compared to rituximab, ofatumumab mediates 
more potent ADCC and complement-dependent cytotoxicity against CD20+ lymphoma cells 
in vitro (38–41). Moreover, SCID mice bearing disseminated human lymphoma xenografts 
have superior survival after treatment with rhIL-18 plus ofatumumab compared to treatment 
with rhIL-18 plus rituximab (42); GlaxoSmithKline, unpublished data shared with the PI). 
We hypothesized that rhIL-18 and ofatumumab would evoke more effective antitumor 
immune responses than rhIL-18 plus rituximab in patients with lymphoma who have 
undergone PBSCT.
PATIENTS AND METHODS
Patient Selection
Eligible patients included adults (age ≥ 18 years) with histologically confirmed CD20+ B 
cell NHL who had undergone high-dose therapy and autologous PBSCT within 2–6 months 
prior to study enrollment. Patients were required to have ECOG performance status less than 
2 as well as adequate renal, hepatic, and hematologic function. Patients were excluded if 
they had obvious clinical progression of lymphoma after PBSCT, were pregnant or breast-
feeding, were seropositive for HIV or hepatitis B surface antigen, had active hepatitis C 
infection, known symptomatic or untreated leptomeningeal or brain metastases, or major 
uncontrolled co-morbid illnesses.
Study Design
The study was an open-label, non-randomized, dose-escalation phase I clinical trial 
(GlaxoSmithKline Clinical Study OFT116979; ClinicalTrials.gov identifier NCT01768338). 
The study protocol was approved by the Institutional Review Board at Indiana University 
Medical Center (Indianapolis, IN). Written informed consent was obtained from each patient 
prior to enrollment on study. Study drugs SB-485232 (iboctadekin), a rhIL-18 protein 
produced in E. coli, and ofatumumab were supplied by GlaxoSmithKline (Research Triangle 
Park, NC). After the clinical trial was initiated, responsibility for study drugs was transferred 
from GlaxoSmithKline to Novartis (East Hanover, NJ). The IND for iboctadekin and 
Robertson et al. Page 3
J Immunother. Author manuscript; available in PMC 2019 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ofatumumab was held by the principal investigator (MJR). Ofatumumab 1000 mg was given 
by intravenous infusion once per week for four consecutive weeks (on day 1 of weeks 1–4). 
rhIL-18 was given by intravenous infusion over 2 hours once per week for 8 consecutive 
weeks (on day 2 of weeks 1–8). During weeks 1–4 of study, the rhIL-18 infusions were 
started at least 24 hours after initiation of the preceding ofatumumab infusion.
Successive cohorts of 3 patients were planned to receive rhIL-18 in doses of 3, 10, 30, and 
potentially 100 μg/kg. Toxicity was graded using the National Cancer Institute Common 
Toxicity Criteria Version 4.0. Dose-limiting toxicity was defined as any grade 3 or 4 toxicity 
observed during the first 6 weeks of treatment that was assessed to be related to study drug, 
excluding grade 3–4 lymphopenia and grade 3 nausea or vomiting that was responsive to 
supportive care measures.
Prospectively defined biomarker analyses were used to determine whether dose escalation 
should halt at the 30 μg/kg cohort or proceed to the 100 μg/kg cohort. Transient 
lymphopenia is commonly observed after the administration of immunostimulatory 
cytokines and is most likely due to in vivo activation of lymphocytes with their subsequent 
extravasation into tissue spaces and/or infiltration into tumors (7, 43, 44). Transient decrease 
in the absolute number of peripheral blood NK cells after rhIL-18 infusions was considered 
a biomarker for NK cell activation in vivo. Escalation to a 100 μg/kg dose cohort was to be 
undertaken only if an average decrease of less than 80% from baseline NK cell number was 
seen after the first infusion of rhIL-18 in the 30 μg/kg dose cohort.
Pharmacodynamic Studies
Blood samples were collected for analysis of leukocyte markers by flow cytometry prior to 
initiation of ofatumumab infusion on day 1 of week 1 and prior to and 4 hours after initiation 
of the rhIL-18 infusion on day 2 of weeks 1, 4, and 8 of study. Blood samples were collected 
for quantification of plasma IFN-γ and chemokines prior to initiation of ofatumumab 
infusion on day 1 of weeks 1–4 and prior to and 4 and 6 hours after initiation of rhIL-18 
infusion on day 2 of weeks 1, 4, and 8 of study. Peripheral blood mononuclear cells 
(PBMCs) were isolated on a Ficoll-diatrizoate gradient from venous blood samples.
PBMCs were stained directly with fluorochrome-conjugated monoclonal antibodies, 
washed, fixed in 1% formaldehyde, and analyzed by flow cytometry as previously described 
(45) using an FACScan or FACScalibur instrument from Becton Dickinson (San Diego, CA). 
The absolute number of peripheral blood NK cells was calculated by multiplying the total 
lymphocyte count (derived from a routine complete blood count performed at the same time 
a blood sample was obtained for flow cytometry studies) by the percent of cells in a sample 
expressing CD56 in the absence of CD3 (derived from flow cytometric analysis).
Levels of IFN-γ, MIG (CXCL9), and IP-10 (CXCL10) protein in serum samples were 
measured using specific ELISA kits according to the manufacturer’s (R & D Systems, 
Minneapolis, MN) instructions. The lower limit of detection for the IFN-γ ELISA was 8 
pg/mL. For data analysis, samples with IFN-γ levels < 8 pg/mL were assigned a value of 8 
pg/mL. The upper limit of linearity for IP-10 ELISA was 500 pg/mL. For data analysis, 
samples with IP-10 levels exceeding 500 pg/mL were assigned a value of 500 pg/mL.
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Evaluation of Clinical Characteristics and Response
Lymphoma subtypes were designated using the WHO Classification (46). Patients 
designated to have primary refractory disease were those who failed to achieve complete 
response or who developed objective disease progression ≤ 3 months after receiving a first-
line chemotherapy regimen. At the time of PBSCT, patients designated to have 
chemosensitive disease were those who achieved a complete or partial response after 
receiving salvage chemotherapy prior to PBSCT, whereas patients who failed to achieve a 
complete or partial response after salvage chemotherapy were designated to have 
chemorefractory disease. Radiographic evaluation of tumor responses was done as per 
standard practice and was not dictated by the study protocol. Tumor responses were assessed 
using International Workshop Criteria (47).
Statistical Analysis
Analysis of safety and efficacy data was descriptive in nature, with counts and percentages 
determined for categorical data and mean, median, standard deviation, minimum, and 
maximum for continuous data. T-tests were used to compare different time points and 
different dosages for the INF-γ and chemokine data. Statistical tests were conducted using 
SAS version 9.4.
RESULTS
Patient Characteristics
Nine male patients began study drug treatment at a median of 133 days (range, 70 to 175 
days) after PBSCT. The median age of patients enrolled on study was 58 years (Table 1). All 
patients had autologous peripheral blood stem cells collected by apheresis following 
mobilization with filgrastim with (n = 6) or without (n = 3) plerixafor and received high-
dose carmustine/ etoposide/ cytarabine/ melphalan (BEAM) as the preparative regimen prior 
to PBSCT. Supportive care after PBSCT was as previously described (48), except that 
patients did not routinely receive filgrastim support post-transplant.
Seven patients enrolled on study had DLBCL, including 2 patients with primary refractory 
disease and 5 patients with relapsed disease. Biopsy at the time of relapse or disease 
progression preceding PBSCT confirmed DLBCL for all 5 patients with recurrent disease 
and one of the 2 patients with primary refractory disease. One patient with DLBCL had 
biopsy-proven primary refractory disease after R-CHOP therapy and experienced rapid 
disease progression after one cycle of platinum-based salvage chemotherapy. This patient 
underwent PBSCT after responding to local radiation therapy. One patient had advanced 
stage mantle cell lymphoma in first complete response at the time of PBSCT. One patient 
with advanced stage indolent follicular experienced clinically suspected (not biopsy proven) 
transformation to aggressive lymphoma and underwent PBSCT after achieving a second 
complete response following salvage chemotherapy.
Administration of Ofatumumab and rhIL-18 on Study
Three patients each were enrolled in the 3, 10, and 30 μg/kg dose cohorts, respectively. All 9 
patients received the 4 planned infusions of ofatumumab. Six patients received the 8 planned 
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infusions of rhIL-18. One patient with mantle cell lymphoma was taken of study for disease 
progression after receiving 6 of 8 planned doses (at 3 μg/kg) of rhIL-18. One patient with 
DLBCL received 6 of 8 planned doses (at 3 μg/kg) of rhIL-18 due to occurrence of 
asymptomatic grade 3 neutropenia (absolute neutrophil count 525 per μL) during week 7 of 
study. His absolute neutrophil count recovered to 3,800 within 14 days. It was 
retrospectively judged that this transient decline in neutrophils was likely due to delayed-
onset neutropenia from recent ofatumumab infusions rather than due to rhIL-18. One patient 
with DLBCL received 6 of 8 planned doses (at 30 μg/kg) of rhIL-18 before being taken off 
study for disease progression). None of the enrolled patients was taken off study because of 
serious adverse events or failure to tolerate the treatment.
Clinical Toxicity and Laboratory Abnormalities during Administration of Ofatumumab and 
rhIL-18
Clinical adverse events attributed to rhIL-18 are summarized in Table 2. The only grade 3–4 
non-hematologic laboratory abnormality observed during the study was grade 4 
hypomagnesemia that was present at baseline in one patient (Table 3). This was attributed to 
prior chemotherapy. Hematologic toxicity (Table 4) was generally similar to that seen in 
patients receiving rhIL-18 as monotherapy by the same schedule of administration (17). 
Grade 1 adverse events attributed to ofatumumab included fever, chills, flu-like symptoms, 
flushing, headache, nausea, vomiting, diarrhea, and rash (one occurrence of each event). One 
patient had grade 2 fatigue attributed to ofatumumab. Grade 1–2 adverse events attributed to 
ofatumumab were not more common in the higher rhIL-18 dose cohorts as compared to the 
3 μg/kg rhIL-18 dose cohort (data not shown). No grade 3 or 4 symptomatic adverse events 
were attributed to rhIL-18 or ofatumumab
Transient asymptomatic grade 3 neutropenia was seen during week 7 of study in two 
patients, one each in the 3 and 30 μg/kg cohorts; this was ultimately attributed to prior 
ofatumumab infusions and not to rhIL-18. Transient grade 3–4 lymphopenia was considered 
an expected biologic effect of rhIL-18 administration rather than an adverse event. No 
serious adverse events were attributed to ofatumumab or rhIL-18 in this study and a 
maximum tolerated dose of rhIL-18 was not identified.
Effects of rhIL-18 on Peripheral Blood Lymphocytes
The median absolute lymphocyte count of study patients at the time of the first ofatumumab 
infusion was 1,410 cells per μL, which is within the normal range (1,000 – 3,200 cells per 
μL) for our clinical laboratory. However, three patients (subjects 03, 05, and 09) had 
subnormal lymphocyte counts of 800, 500, and 700 cells per μl, respectively, when they 
commenced study drug treatment. The median absolute peripheral blood NK cell count was 
220 cells per μl (range, 84 – 714 cells per μl).
Circulating lymphocytes declined and recovered in a manner similar to that seen in previous 
studies of rhIL-18 monotherapy (16, 17) or rhIL-18 plus rituximab (18). The mean reduction 
from pre-dose levels in the numbers of peripheral blood lymphocytes 4 hours after the first 
rhIL-18 infusion was 66%, 91%, and 81% for the 3, 10, and 30 μg/kg cohorts, respectively. 
Thus, the maximal reduction in circulating lymphocytes was seen in the 10 μg/kg dose 
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cohort. The mean reduction from pre-dose levels in the number of peripheral blood NK cells 
4 hours after the first rhIL-18 infusion was 91%, 96%, and 97% for the 3, 10, and 30 μg/kg 
cohorts, respectively. Therefore, per the protocol-specified NK cell biomarker criteria 
enrollment of a 100 μg/kg dose cohort was not undertaken.
Effects of rhIL-18 on serum levels of IFN-γ and chemokines
Prior to the first infusion of rhIL-18, IFN-γ was undetectable (< 8 pg/mL) in serum samples 
obtained from 8 subjects. Subject 07 had a baseline serum IFN-γ level of 9 pg/mL. IFN-γ 
became detectable in serum samples obtained from 8 subjects at 4 and/or 6 hours after the 
first rhIL-18 infusion. Only subject 03 did not have detectable serum IFN-γ levels during 
rhIL-18 treatment. The peak serum IFN-γ levels seen after the first rhIL-18 infusion were: 
11, 14, and 1 pg/mL for the 3 subjects in the 3 μg/kg cohort; 21, 9, and 14 pg/mL for the 3 
subjects in the 10 μg/kg cohort; and 57, 76, and 62 pg/mL for the 3 subjects in the 30 μg/kg 
cohort. The mean serum IFN-γ levels were not significantly different (P = 0.3632) when 
comparing samples obtained 4 hours after the first rhIL-18 infusion from subjects in the 3 
versus 10 μg/kg dose cohorts. The mean serum IFN-γ levels seen 4 hours after the first 
rhIL-18 infusion were significantly higher in samples obtained from subjects in the 30 μg/kg 
dose cohort compared to the levels seen in the 3 μg/kg (P = 0.0019) and 10 μg/kg (P = 
0.0035) dose cohorts. Similar results were observed for samples obtained 6 hours after the 
first rhIL-18 infusion (data not shown).
The median serum MIG (CXCL9) level prior to study drug treatment was 146 pg/mL (range, 
67 – 785 pg/mL). Three subjects had baseline MIG levels that exceeded the upper limit 
value (199 pg/mL) seen in healthy control volunteers (data provided by manufacturer of the 
ELISA assay). Peak serum MIG levels increased from baseline values by a median of 3.2-
fold (range, 0.9 – 10.9-fold) in samples obtained 4 or 6 hours after the first rhIL-18 infusion. 
Peak serum MIG levels increased by a median of 1.2-fold (range, 0.9 – 3.3-fold) in the 3 
μg/kg cohort, 3.9-fold (range, 1.5 – 5.4-fold) in the 10 μg/kg cohort, and 3.2-fold (range, 3.0 
– 10.9-fold) in the 30 μg/kg cohort.
The median baseline serum IP-10 (CXCL10) level prior to study drug treatment was 207 
pg/mL (range, 67 – 359 pg/mL), which is within the range (38 – 361 pg/mL) seen in healthy 
control volunteers (data provided by manufacturer of the ELISA assay). Serum IP-10 levels 
increased to values exceeding 500 pg/mL (the upper limit of linearity of the ELISA assay) in 
samples obtained from all subjects 4 hours after the first rhIL-18 infusion and remained 
significantly elevated in samples obtained 6 hours post-dose (Table 5). Serum IP-10 levels 6 
days after the first rhIL-18 infusion (on Week 2, Day 1 of study) remained modestly higher 
than baseline levels, but this was statistically significant only for subjects in the 10 μg/kg 
cohort (Table 5).
Progression-Free Survival of Study Patients
One patient with mantle cell lymphoma and one patient with DLBCL progressed while 
receiving rhIL-18 and were taken off study. The other 7 patients with aggressive lymphoma 
(6 DLBCL, 1 presumed transformed lymphoma) are alive and free of lymphoma progression 
with a median follow-up of 41.6+ months (range, 28.6+ to 55.1+ months) after PBSCT.
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DISCUSSION
This phase I study clearly shows that combined therapy with rhIL-18 and ofatumumab is 
feasible after PBSCT for lymphoma. Adverse effects were modest and tolerable and no 
dose-limiting toxicities were observed. Asymptomatic, transient grade 4 neutropenia 
occurred in two subjects. These episodes of neutropenia were attributed to ofatumumab and 
were not associated with fever or infection. A maximum tolerated dose of rhIL-18 has not 
been identified in clinical trials to date. Escalation to a 100 μg/kg dose cohort of rhIL-18 was 
not undertaken in our study based on a prospectively planned NK cell biomarker analysis. 
Given the modest toxicity of rhIL-18 and ofatumumab after PBSCT, combination with 
additional immunotherapeutic agents should be feasible. Rational choices could include 
adding lirilumab to further augment NK cell ADCC against antibody-sensitized lymphoma 
cells (49) and/or adding an immune checkpoint inhibitor (e.g. ipilimumab or anti-PD1 
antibodies) to enhance T cell-mediated antitumor immunity (50, 51).
IFN-γ levels increased in serum of all but one patient given rhIL-18 on this study, consistent 
with our hypothesis that STAT4-deficient lymphocytes after PBSCT would be responsive to 
stimulation with IL-18. IFN-γ can promote the differentiation of Th1 helper effector cells 
(52). IFN-γ secreted by activated NK cells also stimulates production of the CXC 
chemokines MIG (CXCL9) and IP-10 (CXCL10), which contribute to antitumor responses 
by inhibiting tumor angiogenesis and recruiting CXCR3-bearing effector cells (53–55). 
However, IFN-γ induces the expression of indoleamine 2,3-dioxygenase (IDO1) in tumor 
cells, antigen-presenting cells, myeloid-derived suppressor cells, and immune effector cells 
(51, 56). IDO1 is an enzyme that catalyzes the breakdown of the essential amino acid 
tryptophan. IDO1-mediated tryptophan depletion suppresses effector T cell responses (51, 
56). Moreover, IDO1 activity yields immunosuppressive metabolites, such as kynurenine 
and quinolinic acid. These metabolites inhibit the proliferation and cytotoxic function of T 
and NK cells (51, 56). IFN-γ can also induce the expression of PD-L1 on tumor cells (57). 
Therefore, administration of IDO1 inhibitors may be necessary to circumvent IFN-γ-
mediated feedback inhibition of T and NK cells during post-transplant immunotherapy. 
Several oral inhibitors of IDO1 are in clinical development (58).
The efficacy of rhIL-18 and ofatumumab after PBSCT cannot be accurately assessed in this 
phase I clinical trial. Nevertheless, the seven patients who were not taken off study early for 
progressive disease remain alive without evidence of active lymphoma at a median of 3.5 
years post-transplant. Indeed, all of these patients have remained progression free for more 
than 2.4 years post- PBSCT. Historical data indicate that about 3 to 4 of these patients with 
primary refractory or relapsed aggressive lymphoma would have been expected to develop 
disease progression by two years post-transplant. These promising results support continued 
efforts to develop novel approaches to immunotherapy after PBSCT for lymphoma.
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TABLE 1
Characteristics of Study Patients
Age (y), median (range) 58 (42–69)
Histologic subtype of lymphoma
 DLBCL 7
 Follicular lymphoma, grade 2 * 1
 Mantle cell lymphoma 1
Prior rituximab treatment
 With induction chemotherapy 9
 With salvage therapy prior to PBSCT 6
Disease status after salvage therapy (prior to PBSCT)
 First complete remission 1
 Chemosensitive primary refractory disease 1
 Chemorefractory primary refractory disease 1
 Chemosensitive relapsed disease 6
 Complete response 6
 Partial response 3
Disease status at time of study enrollment (after PBSCT)
 Complete response 7
 Partial response 2
*Clinically suspected transformation to aggressive lymphoma
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TABLE 2
Clinical Adverse Events Attributed to rhIL-18
Adverse Event rhIL-18 Doses plus Ofatumumab (1000 mg)
No. Patients with Grade 1–2 Adverse Event (%)*
3 μg/kg (N = 3) 10 μg/kg (N = 3) 30 μg/kg (N = 3) Total (N = 9)
Fever 1 (33) 1 (33) 0 2 (67)
Chills 1 (33) 1 (33) 0 2 (67)
Fatigue 1 (33) 1 (33) 0 2 (67)
Flu-like sympoms 0 1 (33) 0 1 (33)
Nausea 0 1 (33) 0 1 (33)
Anorexia 1 (33) 0 0 1 (33)
Constipation 1 (33) 0 0 1 (33)
Diarrhea 0 0 1 (33) 1 (33)
Abdominal distension 1 (33) 0 0 1 (33)
Abdominal pain 1 (33) 0 0 1 (33)
Back pain 0 1 (33) 0 1 (33)
Headache 1 (33) 0 1 (33) 2 (67)
Unspecified pain 1 (33) 0 0 1 (33)
Skin rash 0 1 (33) 0 1 (33)
*No grade 3 or 4 adverse events were attributed to rhIL-18.
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TABLE 3
Non-hematologic Laboratory Abnormalities (Regardless of Causality)
Laboratory Abnormality
rhIL-18 Doses plus Ofatumumab (1000 mg)
No. Patients with Grade 1–2 / 3–4 Laboratory Abnormality
3 μg/kg (N = 3) 10 μg/kg (N = 3) 30 μg/kg (N = 3) Total (N = 9)
Elevated Bilirubin 0 / 0 1 / 0 0 / 0 1 / 0
Elevated Alkaline Phosphatase 2 / 0 0 / 0 1 / 0 3 / 0
Elevated SGOT 0 / 0 1 / 0 0 / 0 1 / 0
Elevated Creatinine 0 / 0 0 / 0 1 / 0 1 / 0
Hyperglycemia 3 / 0 2 / 0 3 / 0 8 / 0
Hypomagnesemia 0 / 0 0 / 0 0 / 1* 0 / 1*
Hyponatremia 1 / 0 0 / 0 1 / 0 2 / 0
Hypocalcemia 1 / 0 0 / 0 0 / 0 1 / 0
Hypokalemia 1 / 0 1 / 0 0 / 0 2 / 0
Hypoalbuminemia 1 / 0 0 / 0 1 / 0 2 / 0
*Asymptomatic grade 4 hypomagnesemia was present at baseline prior to study drug administration.
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TABLE 4
Hematologic Abnormalities (Regardless of Causality)
Reduction in Level of
rhIL-18 Doses plus Ofatumumab (1000 mg)
No. Patients with Grade 1–2 / 3* Hematologic Abnormality
3 μg /kg (N = 3) 10 μg /kg (N = 3) 30 μg /kg (N = 3) Total (N = 9)
Hemoglobin 3 / 0 3 / 0 1 / 1** 7 / 1**
Platelet count 2 / 0 2 / 0 3 / 0 7@ / 0
Neutrophil count 0 / 1*** 1 / 0 2 / 1*** 3 / 2***
*No grade 4 hematologic abnormalities were seen.
**
Baseline grade 2 anemia increased to grade 3 during study. This increase in toxicity grade was attributed to phlebotomy and not to study drugs.
@All grade 1; no grade 2 thrombocytopenia was seen.
***
Transient asymptomatic grade 3 neutropenia in two patients was attributed to prior ofatumumab infusions.
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TABLE 5
Serum IP-10 Levels after first infusion of rhIL-18
rhIL-18 Dose Cohort
Serum IP-10 Levels (pg/mL; mean ± SD) (P values from t-test comparing post-dose to baseline values)
Baseline (Pre-dose) 4 hours after rhIL-18 dose 6 hours after rhIL-18 dose Week 2, Day 1
3 μg/kg (N = 3) 145 ± 59 500 ± 0 (P = 0.0090) 468 ± 55 (P = 0.0022) 203 ± 51 (P = 0.2675)
10 μg/kg (N = 3) 94 ± 54 500 ± 0 (P = 0.0057) 500 ± 0 (P = 0.0057) 188 ± 23 (P = 0.0499)
30 μg/kg (N = 3) 110 ± 45 500 ± 0 (P = 0.0044) 500 ± 0 (P = 0.0044) 142 ± 27 (P = 0.3544)
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